---
id: longevity-and-healthspan-interventions
name: Longevity & Healthspan Interventions
family: technological
tier: active
url: https://explorer.talin.digital/e/longevity-and-healthspan-interventions/
author: Benjamin Talin
citation: Talin, B. (2026). The Future Explorer. https://explorer.talin.digital (dataset v0.4.0, 2026-11-16)
license: CC-BY-NC-4.0
---

# Longevity & Healthspan Interventions

Medicines and therapies aimed at ageing itself rather than at each disease it brings, one at a time. One idea is to clear out worn-out 'zombie' cells that build up with age. One such drug was tested on 183 people with painful knees, and after twelve weeks it worked no better than a dummy injection. Every human result so far is early and small, and no regulator yet treats ageing as something a drug can be approved for.

> Drugs and therapies aimed at the biology of ageing itself - rather than at each disease it produces, one at a time.

## Maturity
1/5 — Every human result is early and small, and a 183-patient Phase 2 trial of a senolytic missed its primary endpoint. No regulator treats ageing as something a drug can be approved for, and the trial built to change that has not started.

Capability 1 · deployment 1 · absorption 1 · bound by capability · flat

Source: Hickson et al., EBioMedicine 47:446–456 (Sep 2019); Justice et al., EBioMedicine 40:554–563 (Feb 2019); UNITY Biotechnology (17 Aug 2020); AFAR, TAME trial (accessed Sep 2026); Harrison et al., Nature 460 (Jul 2009) (2009–2026)

## What it is
Interventions aimed at the biology of ageing itself - senolytics, metabolic and cellular reprogramming approaches.

## What it does
It targets the upstream driver of most age-related disease at once, rather than treating each disease separately. If it works even partially, the demographic and fiscal consequences are large.

## Common misconception
That the field has demonstrated human results. Animal data is genuinely striking, human trials are early, and this is among the most overclaimed areas in this Compendium.

## Steepens
- Longevity and the Healthspan Gap (longevity-and-the-healthspan-gap) — large
- The Silver Economy (the-silver-economy) — moderate
- The Care Economy (the-care-economy) — moderate
- Fertility Collapse (fertility-collapse) — marginal

## What would change its gradient
- Validated biomarkers of ageing, which would shorten trials from decades to years
- Regulatory recognition of ageing as an indication
- Nothing on the enthusiasm side - funding is not the constraint here
